Patents by Inventor Paul B. Chapman

Paul B. Chapman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIGEN RECOGNIZING RECEPTORS TARGETING GD3 GANGLIOSIDE AND USES THEREOF
    Publication number: 20240042031
    Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target GD3 and cells comprising such GD3-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the GD3-targeted antigen-recognizing receptors for treatment.
    Type: Application
    Filed: September 28, 2023
    Publication date: February 8, 2024
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Christopher S. Hackett, Renier J. Brentjens, Jedd D. Wolchok, Paul B. Chapman, Sarwish Rafiq, Terence Purdon
  • Methods for detecting circulating mutant BRAF DNA
    Patent number: 7442507
    Abstract: The present invention relates to a method for detecting the presence of circulating mutant BRAF DNA, which may be present in circulating melanoma cells or as DNA shed from tumor cells. Methods, compositions and kits which employ one or more sets of BRAF mutant specific primer pairs for detection of circulating mutant BRAF DNA are presented. Also provided are methods for diagnosing and/or determining stage/progression of a melanoma in a mammal based on detection of a BRAF mutant nucleic acid sequence. Such methods are also well suited to monitoring disease activity in patients with active disease or those in remission.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: October 28, 2008
    Assignees: New York University School of Medicine, Memorial Sloan-Kettering Cancer Center
    Inventors: David Polsky, Iman Osman, Paul B. Chapman
  • Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
    Patent number: 6805862
    Abstract: The present invention provides an anti-idiotypic monoclonal antibody which specifically induces an immune response against a glycosphingolipid. Additionally, this invention provides a method of producing the anti-idiotypic monoclonal antibody. Finally, this invention provides a composition of matter comprising an effective amount of a cytokine and a melanoma ganglio-side-specific antibody attached to a carrier.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 19, 2004
    Assignee: Sloan-Kattering Institute For Cancer Research
    Inventors: Paul B. Chapman, Alan N. Houghton
  • Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
    Publication number: 20030035797
    Abstract: The present invention provides an anti-idiotypic monoclonal antibody which specifically induces an immune response against a glycosphingolipid. Additionally, this invention provides a method of producing the anti-idiotypic monoclonal antibody. Finally, this invention provides a composition of matter comprising an effective amount of a cytokine and a melanoma ganglioside-specific antibody attached to a carrier.
    Type: Application
    Filed: August 13, 2002
    Publication date: February 20, 2003
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: Paul B. Chapman, Alan N. Houghton
  • Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
    Patent number: 6432402
    Abstract: The present invention provides an anti-idiotypic monoclonal antibody which specifically induces an immune response against a glycosphingolipid. Additionally, this invention provides a method of producing the anti-idiotypic monoclonal antibody. Finally, this invention provides a composition of matter comprising an effective amount of a cytokine and a melanoma ganglioside-specific antibody attached to a carrier.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: August 13, 2002
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Paul B. Chapman, Alan N. Houghton
  • Anti-idiotypic antibody vaccines
    Patent number: 5792455
    Abstract: A vaccine for stimulating and enhancing in a subject to which the vaccine is administered, production of antibodies which recognize GD3 ganglioside, comprising an effective amount of anti-idiotypic monoclonal antibody, designated BEC2, an effective amount of the appropriate adjuvant and a pharmaceutically acceptable vehicle.
    Type: Grant
    Filed: March 21, 1996
    Date of Patent: August 11, 1998
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Paul B. Chapman, Alan N. Houghton
  • Anti-idiotypic monoclonal antibody that induces an immune response against the ganglioside GD.sub.3 and hybridoma producing said antibody
    Patent number: 5529922
    Abstract: The invention provides an anti-idiotypic monoclonal antibody, IgG2b subclass, which specifically induces an immune response against the GD.sub.3 ganglioside and specifically binds to the binding site of the R24 antibody.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: June 25, 1996
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Paul B. Chapman, Alan N. Houghton